

Richard E. Doblin
3 Francis Street
Belmont, Massachusetts 02478
(617) 276-7806

Education

HARVARD UNIVERSITY, JOHN F. KENNEDY SCHOOL OF GOVERNMENT, Cambridge, Massachusetts
Master of Public Policy, June 1990; Ph.D in Public Policy, June, 2001.

Professional degree in public management and policy analysis. Coursework included empirical methods, management, economics, analytics, criminal justice and drug policy. Masters thesis surveyed oncologists regarding their experiences with the use of marijuana in the treatment of nausea induced by cancer chemotherapy. Dissertation focused on the regulation of the medical uses of psychedelics and marijuana.

NEW COLLEGE OF THE UNIVERSITY OF SOUTH FLORIDA, Sarasota, Florida
Bachelor of Arts, Psychology, May 1987

Coursework included experimental psychology, neurophysiology, psychotherapy research. Thesis was a twenty-five year follow-up study that explored the potential of psychedelic drugs to catalyze mystical experiences.

DR. STAN GROF'S HOLOTROPIC BREATHWORK TRAINING PROGRAM. Certified in 1990 in the first class of Holotropic Breathwork Practitioners.

Professional Experience

Founder and Executive Director, Multidisciplinary Association for Psychedelic Studies, Inc., Sarasota, Florida
May 1986 to Present

Direct scientific and educational non-profit organization chartered to foster medical and scientific research on psychoactive drugs, primarily MDMA. Responsibilities include supporting and supervising animal and human research, protocol design, fundraising, policy analysis, handling governmental and membership relations, organizing conferences, public speaking, publishing newsletters and networking with researchers internationally.

Co-Founder and President, Earth Metabolic Design Laboratory, Inc., Sarasota, Florida, Spring 1984 to Summer 1985

Led scientific and educational non-profit organization which coordinated testimony of medical and scientific community before Drug Enforcement Administration Administrative Law Judge in support of efforts to place MDMA in Schedule 3. Responsibilities included acting as liaison to lawyers, national and international governmental authorities and press. Organized fund-raising, membership and conferences.

Founder and President, Braxas Construction Company, Inc., Sarasota, Florida, Spring 1973-Summer 1982

Designed and built custom and speculation wood homes. Responsible for all construction, contracting, architectural relations, banking, sales and customer relations. Earned Florida State Certified Building Contractor license and Florida Real Estate Sales License.

Publications

- Mithoefer, M.C., Feduccia, A.A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019). "MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials." J. Psychopharmacology. Doi: 10.1007/s00213-019-0524905. Epub 2019 May 7.
- Mithoefer, M.C., Mithoefer, A., Feduccia, A., Jerome, L., Wagner, M., Holland, F., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R. (2019). "S.08.06 MDMA-assisted psychotherapy for PTSD: A promising novel experimental treatment moving into phase 3 trials with FDA breakthrough therapy designation." European Neuropsychopharmacology. 29. S11-S12. doi: 10.1016/j.euroneuro.2018.11.930.

- Hake, H., Davis, J., Wood, R., Tanner, M., Loetz, E.C., Sanchez, A., Ostrovsky, M., Oleson, E.B., Grigsby, J., Doblin, R., Greenwood, B. (2018). "3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiology & Behavior. Dec;199. doi: 10.1016/j.physbeh.2018.12.007.
- Ot'alora G M, Grigsby J, Poulter B, Van Derveer JW 3rd, Giron SG, Jerome L, Feduccia AA, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. (2018). "3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial." J Psychopharmacology. Dec;32(12). Epub 2018 Oct 29.
- Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J, Holland J, Hamilton S, Yazar-Klosinski B, Emerson A, Doblin R. (2018). "3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial." Lancet Psychiatry. 2018 Jun;5(6):486-497. Epub 2018 May 1.
- Feduccia AA, Mithoefer MC, Jerome L, Holland J, Emerson A, Doblin R. (2017). "Response to the Consensus Statement of the PTSD Psychopharmacology Working Group." Biological Psychiatry. Nov 23. (17)32241-2.
- Wagner MT, Mithoefer MC, Mithoefer AT, MacAulay RK, Jerome L, Yazar-Klosinski B, Doblin R. (2017) Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. Journal of Psychopharmacology. Aug;31(8):967-974. Epub 2017 Jun 21.
- Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, Brenneisen R. (2014) Safety and efficacy of LSD-assisted psychotherapy in participants with anxiety associated with life-threatening diseases: a randomized active placebo-controlled phase 2 pilot study. Journal of Nervous and Mental Disease. 202;513: 520.
- Doblin R, Greer G, Holland J, Jerome L, Mithoefer MC, Sessa B. (2014) A reconsideration and response to Parrott AC (2013) "Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research". Human Psychopharmacology. Mar;29(2):105-8.
- Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B, Michel Y, Brewerton TD, Doblin R. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacology. 27(1): 28-39. Epub 2012 Nov 20.
- Mithoefer, M, Wagner, M., Mithoefer A, Jerome, L., Doblin, R. (2010). "The safety and efficacy of 3,4- methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study." J Psychopharmacology: 1-14 (published electronically July 19, 2010).
- Bouso, J.C., Doblin, R., Farré, M., Alcázar, M.A. & Gómez-Jarabo, G. 2008. "MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder." J. of Psychoactive Drugs 40 (3): 225-36.
 - Mithoefer M, Jerome L, Doblin R. (2003). "MDMA ("Ecstasy") and Neurotoxicity." Science, 300: 1504.
 - Doblin R. (2002). "A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA." J. Psychoactive Drugs, 34 (2):185-194.
 - Grinspoon L. and Doblin R. (2001). "Psychedelics as Catalysts of Insight-Oriented Psychotherapy." Social Research, 68 (3): 677-698.
 - Doblin R. (1998). "Dr. Leary's Concord Prison Experiment- A 34-Year Follow-Up." J. Psychoactive Drugs, 30 (4): 419-426.
 - Doblin R. and Kleiman M. (1998). "Survey Research vs Clinical Trials in Evaluating the Medical Utility of Marijuana." Southern Medical Journal, 91 (10), 989-991.
 - Doblin R. and Kleiman M. (1995) "The Medical Use of Marijuana: The Case for Clinical Trials." Journal of Addictive Diseases, Vol. 14 (1): 5-14.
 - Doblin R. (1991) "Pahnke's Good Friday Experiment: A Long-Term Follow-Up and Methodological Critique." Journal of Transpersonal Psychology, 23 (1): 1-28.
 - Doblin R. and Kleiman M. (1991). "Marijuana as Antiemetic Medicine: A survey of oncologists' experiences and attitudes." Journal of Clinical Oncology, 9(7):1314-1319.
 - Doblin R. and Kleiman M. (1991) "The Medical Use of Marijuana." Annals of Internal Medicine, 114 (9):809-10.